Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Kaichun Wu(Moderna Therapeutics (United States)), Anne P. Werner(National Institute of Allergy and Infectious Diseases), Matthew Koch(Moderna Therapeutics (United States)), Angela Choi(Moderna Therapeutics (United States)), Elisabeth Narayanan(Moderna Therapeutics (United States)), Guillaume B. E. Stewart-Jones(Moderna Therapeutics (United States)), Tonya M. Colpitts(Moderna Therapeutics (United States)), Hamilton Bennett(Moderna Therapeutics (United States)), Seyhan Boyoglu-Barnum(National Institute of Allergy and Infectious Diseases), Wei Shi(National Institute of Allergy and Infectious Diseases), Juan I. Moliva(National Institute of Allergy and Infectious Diseases), Nancy J. Sullivan(National Institute of Allergy and Infectious Diseases), Barney S. Graham(National Institute of Allergy and Infectious Diseases), Andrea Carfı́(Moderna Therapeutics (United States)), Kizzmekia S. Corbett(National Institute of Allergy and Infectious Diseases), Robert A. Seder(National Institute of Allergy and Infectious Diseases), Darin K. Edwards(Moderna Therapeutics (United States))
Cited by 472Open Access
Abstract
Variant SARS-CoV-2 and the mRNA-1273 Vaccine How well do serum samples from persons vaccinated with the mRNA-1273 vaccine neutralize the P.1 lineage, the B.1.1.7 lineage, the B.1.1.7 lineage plus t...
Related Papers
No related papers found
Powered by citation graph analysis